The Sundance SCB has the potential for improved outcomes in CLI patients over other available treatment options, and its availability is in the best interest of patients.”įiled Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Regulatory/Compliance, Wall Street Beat Tagged With: Surmodics, SurModics Inc. “This second platform adds to our stable of drug-coated balloon devices and furthers our effort to provide treatment solutions for the entire peripheral anatomy. “The Sundance SCB is intended to address the unmet clinical need in patients with CLI and infrapopliteal arterial disease by providing a revascularization option with a proprietary sirolimus coating,” Maharaj said. SRDX will report 2022 earnings on EPS Estimate 2021 2022 2023 2024 -2.5 0 2.5 Quarterly Numbers Actuals Estimates SRDX will report Q4 2022 earnings on EPS Surprise Estimate. The sirolimus-coated device is designed to enhance endovascular revascularization options for below-the-knee arterial lesions in patients with critical limb ischemia and infrapopliteal arterial disease.
Next reporting date: November 9, 2022: EPS forecast (this quarter)-0.48: Annual. In a separate release earlier this week, Surmodics said its Sundance drug-coated balloon won breakthrough device designation from the FDA. Find real-time SRDX - Surmodics Inc stock quotes, company profile, news and forecasts from CNN Business. SRDX shares dropped -14.6% to $40.56 per share in midday trading today. Surmodics widened its outlook on the rest of the year, saying it now expects to put up adjusted EPS of 14¢ to 44¢, compared with between 26¢ and 36¢ previously, on sales of $87 million to $91 million (compared to prior guidance for between $88.5 million and $91.5 million). I am excited by our achievements to date and look forward to continued progress in 2020.” For their last quarter, Surmodics (SRDX) reported earnings of -0.22 per share, beating the Zacks Consensus Estimate of -0.32 per share.
“In the face of unpredictability related to the paclitaxel debate, our team has demonstrated impressive execution which included completing enrollment for our Transcend clinical trial. “During fiscal 2019, we made important progress across our key strategic objectives while delivering strong organic revenue and solid operational results,” president & CEO Gary Maharaj said in prepared remarks. WhistlinDiesels age is 23 years old Date of birth: July 18th, 1998 In 2014 WhistlinDiesel net worth, income and Youtube channel estimated earnings. 30, moving from red to black on revenue growth of 33.8% compared with Q3 2018.Īdjusted to exclude one-time items, earnings per share were 37¢, 2¢ ahead of Wall Street, where analysts were looking for sales of $28.5 million. Surmodics (NSDQ: SRDX) shares plummeted today despite third-quarter results that topped Wall Street projections.Įden Prairie, Minn.-based Surmodics posted profits of $3.55 million, or 26¢ per share, on sales of $30.8 million for the three months ended Sept.
0 kommentar(er)
